Skip to main content

Nicotine clinical trials at UCSF

5 in progress, 3 open to eligible people

Showing trials for
  • Short-Term Cardiovascular Effects of E-Cigarettes: Influence of E-Liquid pH

    open to eligible people ages 21-70

    This study will examine the short-term cardiovascular (CV) effects of e-liquid pH in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=21). The specific aim of the study is to assess the impact of changes in e-liquid pH on nicotine pharmacokinetics, cardiovascular, and subjective effects of e-cigarettes.

    San Francisco, California and other locations

  • Social Media Intervention to Stop Nicotine and Cannabis Vaping Among Adolescents

    open to eligible people ages 13-21

    Social media based intervention to support teens in their efforts to quit vaping.

    San Francisco, California

  • THC Crossover Study

    open to eligible people ages 21 years and up

    This is a randomized, crossover study enrolling experienced dual cannabis-tobacco smokers (N=18) to describe the differences in THC and toxicant exposure, examining pharmacokinetic, subjective, and cardiovascular effects from smoking and vaping dry herb cannabis. This study will also examine the differences in toxicant exposure and cardiovascular disease risk between smoking cannabis and smoking tobacco cigarettes.

    San Francisco, California and other locations

  • Pharmacokinetics and Pharmacodynamics of Nicotine With Use of Standardized Research Electronic Cigarette (SREC)

    Sorry, not yet accepting patients

    This is a crossover study that will examine use behaviors, chemical exposures, and biological effects of Standardized Research Electronic Cigarette (SREC) compared to usual brand e-cigarette use in natural or synthetic nicotine users.

    San Francisco, California

  • Vaping High vs. Low Nicotine E-Liquid

    Sorry, not yet accepting patients

    This study will examine the effects of electronic cigarette e-liquid nicotine content in a randomized, crossover clinical and behavioral pharmacology study of experienced adult e-cigarette users (N=36). The specific aim is to determine the impact of nicotine content of e-liquid on nicotine pharmacology, systemic exposure to toxic volatile organic compounds, and short-term cardiovascular effects.

    San Francisco, California and other locations

Our lead scientists for Nicotine research studies include .

Last updated: